CD47 Blockade Leads to Chemokine-Dependent Monocyte Infiltration and Loss of B Cells from the Splenic Marginal Zone
- 15 March 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 208 (6) , 1371-1377
Abstract
CD47 is an important innate immune checkpoint through its interaction with its inhibitory receptor on macrophages, signal-regulatory protein α (SIRPα). Therapeutic blockade of CD47–SIRPα interactions is a promising immuno-oncology treatment that promotes clearance of cancer cells. However, CD47–SIRPα interactions also maintain homeostatic lymphocyte levels. In this study, we report that the mouse splenic marginal zone B cell population is dependent on intact CD47–SIRPα interactions and blockade of CD47 leads to the loss of these cells. This depletion is accompanied by elevated levels of monocyte-recruiting chemokines CCL2 and CCL7 and infiltration of CCR2+Ly6Chi monocytes into the mouse spleen. In the absence of CCR2 signaling, there is no infiltration and reduced marginal zone B cell depletion. These data suggest that CD47 blockade leads to clearance of splenic marginal zone B cells. Key Points CD47 blockade leads to rapid but resolvable splenic marginal zone B cell depletion. Anti-CD47 mAb induced CCL2/CCL7 is accompanied by CCR2+ monocyte splenic infiltration.Keywords
Funding Information
- Virginia and D.K. Ludwig Fund for Cancer Research (NA)
- Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation (NA)
- Division of Intramural Research (NA)
- Fairbairn Family Foundation (NA)
- Bay Area Lyme Foundation (NA)
- National Science Foundation (DGE-1147470)
- HHS | National Institutes of Health (5T32AI007290)
- HHS | National Institutes of Health (F32 AI124558-01)
- Stanford University (NA)
This publication has 41 references indexed in Scilit:
- Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcomaProceedings of the National Academy of Sciences, 2012
- The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumorsProceedings of the National Academy of Sciences, 2012
- CD47–signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destructionProceedings of the National Academy of Sciences, 2011
- Functional CD47/signal regulatory protein alpha (SIRPα) interaction is required for optimal human T- and natural killer- (NK) cell homeostasis in vivoProceedings of the National Academy of Sciences, 2011
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin LymphomaCell, 2010
- Macrophages as mediators of tumor immunosurveillanceTrends in Immunology, 2010
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid PhagocytosisCell, 2009
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem CellsCell, 2009
- Dysregulated gene expression networks in human acute myelogenous leukemia stem cellsProceedings of the National Academy of Sciences, 2009
- Essential Role of CCL2 in Clustering of Splenic ERTR-9 + Macrophages during Infection of BALB/c Mice by Listeria monocytogenesInfection and Immunity, 2007